GlassScriptPhysician profile
Tauseef A Khan
NPI 1972585610
$22,767.11
in general payments reported to CMS, 2019-2025
33 companies · $4,545 in 2025
The $4,545 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,072 · 2020: $2,022 · 2021: $1,846 · 2022: $2,245 · 2023: $6,995 · 2024: $4,041 · 2025: $4,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $13K · Food and Beverage: $3,049 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $12,515.73 |
| Food and Beverage | $3,048.54 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $7,337.19 | 2019-2025 | Xience Skypoint, Optis, Diamondback Coronary |
| Medtronic, INC. | $7,299.83 | 2021-2025 | In.Pact Admiral, Abre, Corevalve Evolut R |
| Terumo Medical Corporation | $1,608.00 | 2022-2024 | Glidewire, Glidesheath Slender, Metacross Otw |
| Bard Peripheral Vascular, INC. | $1,155.97 | 2022-2025 | Venovo, Denali Vena Cava Filter |
| Philips North America LLC | $922.87 | 2019-2025 | Igt Devices Systems Undivided |
| Janssen Pharmaceuticals, INC | $722.30 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $591.30 | 2019-2025 | |
| Boston Scientific Corporation | $553.99 | 2022-2025 | Ingevity+, Watchman Flx, Acuity Steerable |
| Merck Sharp & Dohme LLC | $235.93 | 2021-2025 | Verquvo |
| Amgen INC. | $229.42 | 2019-2025 | Repatha, Repatha |
| Astellas Pharma US INC | $226.25 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $221.63 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $219.64 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.96 | 2019-2024 | Jardiance |
| Shockwave Medical, INC | $190.17 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $179.28 | 2019-2024 | Farxiga |
| Abiomed | $124.32 | 2024-2025 | Impella |
| Sanofi-Aventis U.S. LLC | $105.11 | 2019-2022 | |
| Esperion Therapeutics, INC. | $91.77 | 2021-2024 | Nexletol |
| W. L. Gore & Associates, INC. | $87.31 | 2020-2021 | |
| Amarin Pharma, INC. | $83.29 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $62.74 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $57.38 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.84 | 2022-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $37.96 | 2024 | Arcalyst |
| Novo Nordisk INC | $34.33 | 2025 | Wegovy |
| Teleflex LLC | $29.82 | 2023-2024 | Guideliner, Chocolate |
| Bridgebio Pharma, INC. | $26.35 | 2025 | Attruby |
| Irhythm Technologies, INC. | $25.72 | 2020 | |
| Lantheus Medical Imaging, INC. | $22.40 | 2023 | Definity |
| Cardiovascular Systems INC. | $13.79 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.68 | 2019 | |
| Medtronic Vascular, INC. | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tauseef Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.